
Jian Zhao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7934896/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Efficient drug delivery by novel cell-penetrating peptide derived from Midkine, with two heparin binding sites braced by a length-specific helix. Journal of Drug Targeting, 2022, 30, 326-333.	4.4	3
2	Raddeanin A synergistically enhances the anti-tumor effect of MAP30 in multiple ways, more than promoting endosomal escape. Toxicology and Applied Pharmacology, 2022, 449, 116139.	2.8	1
3	Constructing a better binding peptide for drug delivery targeting the interleukin-4 receptor. Journal of Drug Targeting, 2020, 28, 970-981.	4.4	2
4	Analysis of Triterpenoid Saponins Reveals Insights into Structural Features Associated with Potent Protein Drug Enhancement Effects. Molecular Pharmaceutics, 2020, 17, 683-694.	4.6	3
5	Effective Therapeutic Drug Delivery by GALA3, an Endosomal Escape Peptide with Reduced Hydrophobicity. Journal of Membrane Biology, 2020, 253, 139-152.	2.1	12
6	Screening and characterization of a novel highâ€efficiency tumorâ€homing cellâ€penetrating peptide from the buffalo cathelicidin family. Journal of Peptide Science, 2019, 25, e3201.	1.4	11
7	Real-Time Quantitative PCR Analysis of the Expression Pattern of the Hypoglycemic Polypeptide-P Gene in Momordica charantia. Genes, 2019, 10, 1044.	2.4	Ο
8	Screening novel β-galactosidases from a sequence-based metagenome and characterization of an alkaline β-galactosidase for the enzymatic synthesis of galactooligosaccharides. Protein Expression and Purification, 2019, 155, 104-111.	1.3	14
9	Structure optimisation to improve the delivery efficiency and cell selectivity of a tumour-targeting cell-penetrating peptide. Journal of Drug Targeting, 2018, 26, 777-792.	4.4	12
10	Enhanced anticancer effect of MAP30–S3 by cyclosproin A through endosomal escape. Anti-Cancer Drugs, 2018, 29, 736-747.	1.4	6
11	Effectively enhancing cytotoxic and apoptotic effects of alphaâ€momorcharin by integrating a heparinâ€binding peptide. Biotechnology and Applied Biochemistry, 2017, 64, 918-926.	3.1	3
12	A novel trichosanthin fusion protein with increased cytotoxicity to tumor cells. Biotechnology Letters, 2017, 39, 71-78.	2.2	8
13	Enhanced anti-tumor activity of trichosanthin after combination with a human-derived cell-penetrating peptide, and a possible mechanism of activity. Fìtoterapìâ, 2016, 112, 183-190.	2.2	11
14	The heparin-binding domain of HB-EGF as an efficient cell-penetrating peptide for drug delivery. Journal of Peptide Science, 2016, 22, 689-699.	1.4	13
15	Evaluating the translocation properties of a new nuclear targeted penetrating peptide using two fluorescent markers. Journal of Drug Targeting, 2015, 23, 444-452.	4.4	6
16	Enhancing tumor-specific intracellular delivering efficiency of cell-penetrating peptide by fusion with a peptide targeting to EGFR. Amino Acids, 2015, 47, 997-1006.	2.7	15
17	Recombinant expression and purification of a MAP30-cell penetrating peptide fusion protein with higher anti-tumor bioactivity. Protein Expression and Purification, 2015, 111, 9-17.	1.3	24
18	A role of MMP-14 in the regulation of invasiveness of nasopharyngeal carcinoma. Tumor Biology, 2015, 36, 8609-8615.	1.8	8

Jian Zhao

#	Article	IF	CITATIONS
19	Molecular diversity and hypoglycemic polypeptide-P content of <i>Momordica charantia</i> in different accessions and different seasons. Journal of the Science of Food and Agriculture, 2015, 95, 1328-1335.	3.5	8
20	Expression and Characterization of a Novel Enantioselective Lipase from Aspergillus fumigatus. Applied Biochemistry and Biotechnology, 2012, 168, 1820-1833.	2.9	8
21	Tandem Multimer Expression and Preparation of Hypoglycemic Peptide MC6 from Momordica charantia in Escherichia coli. Applied Biochemistry and Biotechnology, 2012, 166, 612-619.	2.9	14
22	A novel human derived cell-penetrating peptide in drug delivery. Molecular Biology Reports, 2011, 38, 2649-2656.	2.3	23
23	Expression and Characterization of a Novel Lipase from Aspergillus fumigatus with High Specific Activity. Applied Biochemistry and Biotechnology, 2011, 165, 949-962.	2.9	37
24	Gene cloning and expression of a novel hypoglycaemic peptide from <i>Momordica charantia</i> . Journal of the Science of Food and Agriculture, 2011, 91, 2443-2448.	3.5	24
25	Significantly Improved Expression and Biochemical Properties of Recombinant Serratia marcescens Lipase as Robust Biocatalyst for Kinetic Resolution of Chiral Ester. Applied Biochemistry and Biotechnology, 2010, 162, 2387-2399.	2.9	18
26	Biochemical properties and potential applications of an organic solvent-tolerant lipase isolated from Serratia marcescens ECU1010. Process Biochemistry, 2008, 43, 626-633.	3.7	86